The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade
Despite the therapeutic success of immune checkpoint blockade (ICB) therapy against multiple tumors, many patients still do not benefit from ICB. In particular, high-grade brain tumors, such as glioblastoma multiforme (GBM), have a very low response rate to ICB, resulting in several failed clinical...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1044544/full |
| _version_ | 1811178109333929984 |
|---|---|
| author | Jang Hyun Park In Kang Heung Kyu Lee |
| author_facet | Jang Hyun Park In Kang Heung Kyu Lee |
| author_sort | Jang Hyun Park |
| collection | DOAJ |
| description | Despite the therapeutic success of immune checkpoint blockade (ICB) therapy against multiple tumors, many patients still do not benefit from ICB. In particular, high-grade brain tumors, such as glioblastoma multiforme (GBM), have a very low response rate to ICB, resulting in several failed clinical trials. This low response rate might be caused by a lack of understanding of the unique characteristics of brain immunity. To overcome this knowledge gap, macroscopic studies of brain immunity are needed. We use single cell RNA sequencing to analyze the immune landscape of the tumor microenvironment (TME) under anti-PD-1 antibody treatment in a murine GBM model. We observe that CD8 T cells show a mixed phenotype overall that includes reinvigoration and re-exhaustion states. Furthermore, we find that CCL5 induced by anti-PD-1 treatment might be related to an increase in the number of anti-inflammatory macrophages in the TME. Therefore, we hypothesize that CCL5-mediated recruitment of anti-inflammatory macrophages may be associated with re-exhaustion of CD8 T cells in the TME. We compare our observations in the murine GBM models with publicly available data from human patients with recurrent GBM. Our study provides critical information for the development of novel immunotherapies to overcome the limitations of anti-PD-1 therapy. |
| first_indexed | 2024-04-11T06:13:48Z |
| format | Article |
| id | doaj.art-29618a5069e14c79a15faf220c150e20 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T06:13:48Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-29618a5069e14c79a15faf220c150e202022-12-22T04:41:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-12-011310.3389/fimmu.2022.10445441044544The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockadeJang Hyun ParkIn KangHeung Kyu LeeDespite the therapeutic success of immune checkpoint blockade (ICB) therapy against multiple tumors, many patients still do not benefit from ICB. In particular, high-grade brain tumors, such as glioblastoma multiforme (GBM), have a very low response rate to ICB, resulting in several failed clinical trials. This low response rate might be caused by a lack of understanding of the unique characteristics of brain immunity. To overcome this knowledge gap, macroscopic studies of brain immunity are needed. We use single cell RNA sequencing to analyze the immune landscape of the tumor microenvironment (TME) under anti-PD-1 antibody treatment in a murine GBM model. We observe that CD8 T cells show a mixed phenotype overall that includes reinvigoration and re-exhaustion states. Furthermore, we find that CCL5 induced by anti-PD-1 treatment might be related to an increase in the number of anti-inflammatory macrophages in the TME. Therefore, we hypothesize that CCL5-mediated recruitment of anti-inflammatory macrophages may be associated with re-exhaustion of CD8 T cells in the TME. We compare our observations in the murine GBM models with publicly available data from human patients with recurrent GBM. Our study provides critical information for the development of novel immunotherapies to overcome the limitations of anti-PD-1 therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1044544/fullGBM - Glioblastoma multiformePD-1CD8 T cellCCL5 - chemokine ligand 5tumor microenvirenment |
| spellingShingle | Jang Hyun Park In Kang Heung Kyu Lee The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade Frontiers in Immunology GBM - Glioblastoma multiforme PD-1 CD8 T cell CCL5 - chemokine ligand 5 tumor microenvirenment |
| title | The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade |
| title_full | The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade |
| title_fullStr | The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade |
| title_full_unstemmed | The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade |
| title_short | The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade |
| title_sort | immune landscape of high grade brain tumor after treatment with immune checkpoint blockade |
| topic | GBM - Glioblastoma multiforme PD-1 CD8 T cell CCL5 - chemokine ligand 5 tumor microenvirenment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1044544/full |
| work_keys_str_mv | AT janghyunpark theimmunelandscapeofhighgradebraintumoraftertreatmentwithimmunecheckpointblockade AT inkang theimmunelandscapeofhighgradebraintumoraftertreatmentwithimmunecheckpointblockade AT heungkyulee theimmunelandscapeofhighgradebraintumoraftertreatmentwithimmunecheckpointblockade AT janghyunpark immunelandscapeofhighgradebraintumoraftertreatmentwithimmunecheckpointblockade AT inkang immunelandscapeofhighgradebraintumoraftertreatmentwithimmunecheckpointblockade AT heungkyulee immunelandscapeofhighgradebraintumoraftertreatmentwithimmunecheckpointblockade |